Oppenheimer Touts Boston Scientific Corporation (BSX) as the Best Large-Cap MedTech

Group 1 - Boston Scientific Corporation (BSX) is recognized as one of the best defensive stocks to buy, with an upgrade from Oppenheimer to 'Outperform' and a price target of $125 [1][2] - The company has shown a strong performance with a revenue growth of 21.44% over the past 12 months, supported by a robust merger and acquisition strategy [2] - Boston Scientific is projected to have a compound annual growth rate (CAGR) of 11%-13%, indicating a positive outlook for a highly diversified company in the healthcare sector [3] Group 2 - The company achieved a 17% organic revenue growth in the second quarter of 2025, with earnings per share increasing by 23% [3] - Boston Scientific develops and manufactures innovative medical devices and solutions for various complex medical conditions, including cardiovascular, respiratory, digestive, neurological, and urological diseases [4]